<DOC>
	<DOCNO>NCT00592618</DOCNO>
	<brief_summary>Sleep study ESRD patient identify increased prevalence Sleep Apnea . Based current knowledge , treatment aim reduce oxidative stress might improve Sleep Apnea HD patient . The aim study investigate effect N-acetylsysteine Sleep Apnea HD patient .</brief_summary>
	<brief_title>Effect NAC Sleep Apnea</brief_title>
	<detailed_description>Background Cardiovascular disease commonest cause morbidity mortality chronic dialysis patient [ 1 ] . Sleep study ESRD patient identify increased prevalence sleep apnea ( SA ) , obstructive ( OSA ) central ( CSA ) origin [ 2 ] . The reported prevalence SA patient ESRD range 50 % 70 % [ 3 ] , dramatically high estimate prevalence 2 % 4 % general population [ 4 ] . SA recognize novel risk factor cardiovascular disease general population [ 5 ] . Recent evidence show severity SA hemodialysis patient associate severity coronary artery calcification [ 6 ] . Underlying mechanisms SA adversely affect cardiovascular morbidity mortality fully establish yet . The presence untreated SA may impair fluid balance , cardiovascular function increase mortality abnormal vagal sympatomimetic responces hypoxia [ 7 ] . One intriguing possibility oxidative stress , implicate cardiovascular disease patient ESRD [ 8 ] . Recent study demonstrate association SA decrease antioxidant status hemodialysis patient [ 6 ] . Repeated apnea-related hypoxic event patient SA may trigger elevated oxidative stress [ 9 ] . In general population , treatment SA CPAP improve oxygenation sleep quality life [ 10 ] . In ESRD population , CPAP use preliminary study 8 patient improvement nocturnal oxygenation 5 6 patient report improved daytime alertness [ 11 ] . Unfortunately , CPAP application may stressful , poorly tolerate disturb night sleep . Hanly Pierratos suggest SA hemodialysis patient may consequence inadequate treatment uremia standard 4-hours thrice-weekly HD procedure [ 12 ] . This group report intensive nocturnal HD 8 hour 6-7 time per week reduce severity SA , although patient continue suffer frequent arousal , diminish sleep time , REM sleep sleep efficiency [ 12 ] . Restoration normal kidney function transplantation may lead reversal SA [ 13 , 14 ] . Several experimental clinical study show increased oxidative stress dialysis patient may due inhibition nitric oxide ( NO ) synthesis ADMA ( Asymmetric Dimethylarginine ) , know endogenous inhibitor NO synthetase [ 15 ] . ADMA may significantly reduce dialysis [ 16 ] . Metabolism ADMA primarily enzyme DDAH , activity decrease inflammation , oxidative stress , diabetes mellitus hypercholesterolemia [ 17 ] . It propose circulate ADMA may one mechanism accounting resistant hypertension overfluid dialysis patient [ 17 ] . Based current knowledge , treatment aim reduce oxidative stress decrease ADMA level [ 17 ] , logical suggest therapy might improve SA HD patient . One preliminary study effect antioxidant Vitamin E show small beneficial effect ADMA chronic kidney disease [ 19 ] . In opinion , worth check ability antioxidant therapy produce favorable effect parameter SA dialysis patient . N-Acetylcysteine ( NAC ) active antioxidant prove safe beneficial hemodialysis patent [ 19 ] . In recent study , NAC effectively reduce ototoxic effect gentamicin chronic hemodialysis patient [ 20 , 21 ] . Cheap safe drug therapy may appear cost effective resource consume therapy CPAP readily available treatment prolong every night hemodialysis kidney transplantation . The aim study investigate effect N-acetylsysteine SA HD patient . Methods . Study population . The study include 20 patient ESRD , treat chronic hemodialysis Assaf Harofeh Medical Center suffer sleep disturbance , frequent arousal , snore , daytime sleepiness . Patients exclude study : 1 . Recently start treated chronic dialysis : le 3 month . 2 . Survived recent major illness , require hospitalisation last 3 month . 3 . Patients acute renal failure 4 . Currently treat antioxidant ( NAC , vitamin E ets . ) 5 . Current use sleep pill Study protocol . We plan study prospective cross-sectional study every patient serve his/her control . Al patient continue previous dialysis drug regimen . The presence severity SA access use overnight polysomnography Sleep Laboratory . After performance baseline overnight polysomnography patient receive orally NAC 1200 mg x 2/day 4 week . At end therapy , follow overnight polysomnography examination perform . The clinical monitoring patient include : 1 . Blood Pressure Heart Rate - dialysis session 3 time week . . 2. Review medication dose . 3 . Body weight - dialysis session 3 time week 4 . Dialysis adequacy : Kt/V study start end . 5 . Biochemical study : full chemistry , bicarbonate , ADMA , DDAH , NO - baseline follow visit . Statistical analysis The statistical analysis perform use statistical software SPSS-version 10 . Parametric data express mean Â± standard deviation compare standard t-test . Non-parametric data compare use chi square test . p value 0.05 less consider significant . References 1 . United States Renal Data System . Patient mortality survival . USRDS Annual Report . Am J Kidney Dis 1997 ; 30 [ Suppl . 1 ] : s91-s101 2 . Chakravorty I , Shastry M , Farrington K. Sleep apnoea end-stage renal disease : short review mechanisms potential benefit treatment . Nephrol Dial Transplant 2007 ; 22:28-31 3 . Kraus M , Hamburger R. Sleep apnea renal failure . Adv Perit Dial 1997 ; 13:88-92 4 . Young T , Palta M , Dempsey J , Skatrud J , Weber S , Badr S. The occurrence sleep-disordered breathing among middle-aged adult . NEJM 1993 ; 328:1230-35 5 . Wolk R , Kara T , Somers V. Sleep-disordered breathe cardiovascular disease . Circulation 2003 ; 108:9-12 6 . Jung H , Han H , Lee J . Sleep apnea , coronary artery disease , antioxidant status hemodialysis patient . AJKD 2005 ; 45:875-882 7 . Zoccali C. Sleep apnoea nocturnal hypoxaemia dialysis patient : mere risk-indicators causal factor cardiovascular disease ? Nephrol Dial Transplant 2000 , 15:1919-21 8 . Boaz M , Matas Z , Biro A , Katzir Z , Green M , Fainaru M , Smetana S. Serum malondialdehyde prevalent cardiovascular disease hemodialysis . Kidney Int 1999 ; 56:1078-83 9 . Lavie L. Obstructive sleep apnoea syndrome -- oxidative stress disorder . Sleep Med Rev 2003 ; 7:35-51 10 . D'Ambrosio C , Bowman T , Mohsenin V. Quality life patient obstructive sleep apnea : effect nasal continuous positive airway pressure -- prospective study.Chest 1999 ; 115:123-29 11 . Pressman M , Benz R , Schleifer C , Peterson D. Sleep disorder breathe ESRD : acute beneficial effect treatment nasal continuous positive airway pressure . Kidney Int 1993 ; 43:1134-39 . 12 . Hanly P , Pierratos A . Improvement sleep apnea patient chronic renal failure undergo nocturnal hemodialysis . N Engl J Med 2001 ; 344:102-7 13 . Auckley D , Schmidt-Nowara W , Brown L. Reversal sleep apnea hypopnea syndrome end-stage renal disease kidney transplantation . Am J Kidney Dis 1999 ; 34:739-744 14 . Langevin B , Fougue D , Leger P , Robert D. Sleep apnea syndrome end-stage renal disease . Cure renal transplantation . Chest 1993 ; 103:1330-1335 15 . Vallance P , Leone A , Calver A , Collier J , Moncada S. Accumulation endogenous inhibitor nitric oxide synthesis chronic renal failure . Lancet . 1992 Mar 7 ; 339 ( 8793 ) :572-5 . 16 . Kielstein J , Boger R , Bode-Boger S et al . Asymmetric Dimethylarginine Plasma Concentrations Differ Patients End-Stage Renal Disease . J Am Soc Nephrol 1999 ; 10:594-600 17 . Kielstein J , Zoccali C. Asymmetric dimethylarginine : cardiovascular risk factor uremic toxin come age ? Am J Kidney Dis . 2005 ; 46 ( 2 ) :186-202 . 18 . Saran R , Novak J , Desai A et al . Impact vitamin E plasma asymmetric dimethylarginine ( ADMA ) chronic kidney disease ( CKD ) : pilot study . Nephrol Dial Transplant . 2003 Nov ; 18 ( 11 ) :2415-20 . 19 . Tepel M , van der Giet M , Statz M et al . The antioxidant acetylcysteine reduces cardiovascular event patient end-stage renal failure : randomize , control trial . Circulation . 2003 Feb 25 ; 107 ( 7 ) :992-5 . 20 . Feldman L , Efrati S , Abramsohn R , Yarovoy I , Gersch E , Eviatar E , Averbukh Z , Weissgarten J. N-Acetylcysteine prevention gentamicin-induced ototoxicity hemodialysis patient . J Am Soc Nephrol 2006 ; 17 ( Suppl ) : 22A 21 . Feldman L , Efrati S , Eviatar E , Abramsohn R , Yarovoy I , Gersch E , Averbukh Z , Weissgarten J. N-Acetylcysteine ameliorate gentamicin-induced ototoxicity hemodialysis patient . Kidney Int 2007 ( press )</detailed_description>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>The study include 20 patient ESRD , treat chronic hemodialysis Assaf Harofeh Medical Center suffer sleep disturbance , frequent arousal , snore , daytime sleepiness . Patients exclude study : Recently start treated chronic dialysis : le 3 month . Survived recent major illness , require hospitalisation last 3 month . Patients acute renal failure Currently treat antioxidant ( NAC , vitamin E ets . ) Current use sleep pill</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>ESRD</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Sleep Apnea</keyword>
</DOC>